MedTrace Logo

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

NCT03882307 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-26

No results posted yet for this study

Summary

Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma..

Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population .

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

sofosbuvir and daclatasvir

oral tablets

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • hayam hamdy, master deree · faculty of medicine,medical microbiology department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2022-11-30
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03882307 on ClinicalTrials.gov